Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $1.11, Beats on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
November 6, 2024 4:05 PM EST 14% year-over-year revenue increase from combined key growth drivers:
Xywav®, Epidiolex® and Rylaze®
2024 total revenue guidance affirmed at $4.0 to $4.1 billion
Zanidatamab 2L BTC PDUFA date of November 29, 2024
Plan to submit sNDA for Zepzelca® in 1L ES-SCLC in 1H25
DUBLIN, Nov. 6, 2024 Â /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2024 and... More
